Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR -mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Shun Lu,Jianying Zhou,Hong Jian,Lin Wu,Ying Cheng,Yun Fan,Jian Fang,Gongyan Chen,Zhihong Zhang,Dongqing Lv,Liyan Jiang,Rong Wu,Xiangming Jin,Xiaodong Zhang,Junhong Zhang,Conghua Xie,Gengyun Sun,Dongning Huang,Jiuwei Cui,Renhua Guo,Zhigang Han,Zhendong Chen,Jin Liang,Wu Zhuang,Xingsheng Hu,Aimin Zang,Yi Zhang,Shundong Cang,Yuanbo Lan,Xi Chen,Laiyu Liu,Xingya Li,Jun Chen,Rui Ma,Yanzhen Guo,Ping Sun,Panwen Tian,Yueyin Pan,Zhe Liu,Peiguo Cao,Lieming Ding,Yang Wang,Xiaobin Yuan,Pengxiang Wu
DOI: https://doi.org/10.1016/s2213-2600(23)00183-2
IF: 102.642
2023-05-26
The Lancet Respiratory Medicine
Abstract:Summary Background Befotertinib (D-0316) is a novel, selective oral third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor. This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as a first-line treatment for patients with EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC). Methods This study was a multicentre, open-label, randomised, controlled phase 3 study at 39 hospitals in China. Eligible patients were 18 years of age or older, had histologically confirmed locally advanced or metastatic stage IIIB, IIIC, or IV unresectable NSCLC, and had confirmed exon 19 deletions or exon 21 Leu858Arg mutation. Patients were randomly assigned (1:1) via an interactive web response system to receive either oral befotertinib (75–100 mg once daily) or oral icotinib (125 mg three times per day) in 21-day cycles until disease progression or withdrawal criteria were met. Randomisation was stratified by type of EGFR mutation, CNS metastasis status, and gender, and participants, investigators, and data analysts were not masked to treatment allocation. The primary endpoint was independent review committee (IRC)-assessed progression-free survival in the full analysis set, which comprised all randomly assigned patients. All patients who received at least one dose of the study drug were included in safety analyses. This study was registered with ClinicalTrials.gov , NCT04206072 , and the overall survival follow-up is still in progress. Findings Between Dec 24, 2019, and Dec 18, 2020, 568 patients were screened, of whom 362 were randomly assigned to the befotertinib (n=182) or icotinib (n=180) group; all 362 patients were included in the full analysis set. Median follow-up was 20·7 months (IQR 10·2–23·5) in the befotertinib group and 19·4 months (10·3–23·5) in the icotinib group. Median IRC-assessed progression-free survival was 22·1 months (95% CI 17·9–not estimable) in the befotertinib group and 13·8 months (12·4–15·2) in the icotinib group (hazard ratio 0·49 [95% CI 0·36–0·68], p<0·0001). Grade 3 or higher treatment-related adverse events occurred in 55 (30%) of 182 patients in the befotertinib group and in 14 (8%) of 180 patients in the icotinib group. Treatment-related serious adverse events were reported in 37 (20%) patients in the befotertinib group and in five (3%) patients in the icotinib group. Two (1%) patients in the befotertinib group and one (1%) patient in the icotinib group died due to treatment-related adverse events. Interpretation Befotertinib demonstrated superior efficacy compared with icotinib in first-line treatment for patients with EGFR mutation-positive NSCLC. Although serious adverse events were more common in the befotertinib than the icotinib arm, the safety profile of befotertinib was manageable overall. Funding Betta Pharmaceuticals (China). Translation For the Chinese translation of the abstract see Supplementary Materials section.
respiratory system,critical care medicine